1,988
-2.55%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genexine
Its shares trade on KOSDAQ under the ticker 095700.KQ. It has been listed since 15 September 2009. In the fiscal year to 31 December 2025, it reported revenue of ₩4.57bn and a net loss of ₩27.22bn. At that date it held total assets of ₩371.27bn and shareholders' equity of ₩246.76bn.
Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Sept 2009
- Employees
- 161
- Website
- genexine.com ↗
Leadership
Pay as last reported
- Mr. Yeong Cheol SungChairman of the Board, since 2021₩2.13bn
- Mr. Jeong Won WooPresident, Director, since 2021
- Mr. Seong Jun HongChief Executive Officer, Chief Financial Officer, Vice President, Director, since 2021
- Mr. Jang Hui LeeManaging Director
- Mr. Seong Gi BaekInternal Auditor
- Mr. Min Gyu HuhAssistant Managing Director
- Mr. Hyeon Cheol JeonInternal Auditor
- Mr. Gi Wan KimAssistant Managing Director
- Mr. Gi Yong KimAssistant Managing Director
- Mr. Yeong Jin KimOther Non-Executive Director
- Mr. Hyeok Jong LeeOther Non-Executive Director, since 2021
- Mr. Jin Geon BaeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genexine Inc has developed a strong portfolio of innovative pharmaceutical products that have gained recognition for their effectiveness in treating various diseases.
- The company has a skilled and experienced team of researchers and scientists who continue to drive innovation and develop novel therapeutics.
- Genexine Inc has established strategic partnerships with leading global pharmaceutical companies, allowing for collaboration and access to additional resources and markets.
Weaknesses
- Genexine Inc relies heavily on external partnerships and collaborations, which may pose risks in terms of control over intellectual property rights and potential conflicts of interest.
- The company faces significant competition in the pharmaceutical industry, making it essential to continuously invest in research and development to stay ahead.
- Genexine Inc may face challenges in navigating regulatory frameworks and obtaining necessary approvals for its products in different markets, leading to potential delays and increased costs.
Opportunities
- The pharmaceutical industry is experiencing a growing demand for innovative therapies and treatments, creating opportunities for Genexine Inc to expand its market presence.
- Advancements in technology and genomics offer potential for Genexine Inc to develop personalized medicine and targeted treatments, catering to specific patient populations.
- Global population growth and aging demographics present an opportunity for Genexine Inc to develop and market products targeting age-related diseases and healthcare needs.
Threats
- The pharmaceutical industry is subject to stringent regulations and compliance requirements, which can significantly impact the development, approval, and commercialization of Genexine Inc's products.
- Intense competition within the industry, combined with the threat of new market entrants, may pose challenges for Genexine Inc in terms of market share and pricing strategies.
- Economic and geopolitical factors can influence market conditions and affect Genexine Inc's ability to expand into new markets or maintain existing operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.